Private ptosis (droopy eyelid) surgery cost UK 2026

What is ptosis (droopy upper eyelid)?

Ptosis is an abnormally low resting position of the upper eyelid relative to the pupil. It is measured clinically using the margin reflex distance 1 (MRD1) — the millimetres from the centre of the pupil light reflex to the upper eyelid margin in primary gaze. A normal MRD1 is 4–4.5 mm; an MRD1 of 2 mm or less is severe and almost always functionally significant, an MRD1 of 2–3 mm is moderate, and an MRD1 of 3–4 mm is mild. Surgical decision-making turns on three numbers: MRD1 (how low), levator function (Berke method — the upper-lid excursion in millimetres from extreme downgaze to extreme upgaze, with brow held flat) and the response to phenylephrine 2.5 per cent (a topical Müller-muscle stimulant that mimics what a posterior MMCR can deliver).

Ptosis is classified by mechanism: aponeurotic (involutional) ptosis — by far the most common cause in adults — is caused by age-related dehiscence or attenuation of the levator aponeurosis from its tarsal insertion, with a typically good levator function (12–15 mm) and a high or absent lid crease; congenital ptosis is caused by a dystrophic levator muscle replaced with fibrous tissue from birth, typically with a poor levator function (4–8 mm) and a poor / absent lid crease; neurogenic ptosis arises from third cranial nerve palsy (often diabetic microvascular or compressive) or Horner's syndrome (sympathetic chain interruption with a typical 1–2 mm MRD1 deficit, miosis, anhidrosis); myogenic ptosis is caused by myasthenia gravis (fatigable, with ice-pack test response), chronic progressive external ophthalmoplegia (CPEO), oculopharyngeal muscular dystrophy (OPMD) and myotonic dystrophy; mechanical ptosis from an eyelid lesion, chalazion or tumour weighing the lid down; and traumatic ptosis from levator disinsertion after orbital injury or surgery.

Functional consequences are real and measurable. A drooping upper eyelid that crosses the upper pupillary margin reduces the superior visual field by 20–40 degrees, which produces a 12–30 per cent loss on Humphrey or Goldmann visual field perimetry and is the threshold for medical (rather than cosmetic) classification in UK insurer policies. Patients compensate with a chronic brow hyperaction (raising the brow with the frontalis muscle), which produces forehead furrows, frontal headaches and a tired appearance; some develop a chin-up head posture. Ptosis surgery corrects the eyelid position itself, restores the superior visual field, allows the brow to relax to its natural rest position, and addresses the cosmetic asymmetry — in that order of priority.

UK 2026 ptosis surgery pricing, in detail

The following pricing reflects a CQC-registered UK oculoplastic sample audited against published 2024 to 2026 self-pay tariffs from the major UK oculoplastic centres. All-inclusive means consultation, imaging, theatre, anaesthetist (where relevant), implants / sling material, and the standard 1-week, 6-week and 3-month follow-up reviews.

Itemised pricing should always split the consultant assessment, perimetry, anaesthetic, theatre and any sling material. If you are exploring a wider upper-eyelid package, the companion private blepharoplasty price guide covers excess skin and orbital fat correction; ptosis surgery addresses the eyelid level itself, blepharoplasty addresses the skin and fat above it — they are commonly combined in the same operation.

What should be included in a private ptosis surgery package in the UK in 2026?

A defensible UK 2026 private ptosis package is built around a structured oculoplastic work-up, intra-operative confirmation of lid level, and a 3-month outcome review with objective MRD1 documentation. Beware of fees that look low until you tot up the "extras".

• Consultant oculoplastic assessment — slit-lamp, MRD1, MRD2, palpebral fissure height, levator function (Berke), lagophthalmos with forced closure, Bell's phenomenon, tear meniscus and break-up time, photographic documentation in primary gaze, upgaze and downgaze.
• Mechanism work-up — fatigability for myasthenia, ice-pack test where indicated, pupil examination for Horner's, ocular motility for 3rd nerve palsy and CPEO, family history for congenital and myogenic.
• Phenylephrine 2.5 per cent test — the single most important pre-operative decision point: a 1.5–2 mm lift at 5 minutes predicts a successful posterior MMCR.
• Visual field perimetry — taped and untaped Humphrey 24-2 or Goldmann III/4e for insurance documentation of superior field loss.
• Day-case theatre under local anaesthetic with optional sedation — many surgeons prefer local-only with the patient awake to allow intra-operative cooperation and lid-height check on the table.
• Surgical implants / sling material — autologous fascia lata harvested from the thigh in suitable patients (gold-standard durability) or pre-packed silicone (Crawford) rod for frontalis sling.
• 1-week suture removal — 6/0 Prolene or Nylon skin sutures removed at day 7–10.
• 6-week contour review — final lid height, contour and crease assessment with photographic comparison.
• 3-month outcome review — objective MRD1, symmetry assessment within 0.5 mm, post-op visual field perimetry, patient-reported outcome questionnaire.
• Revision policy — clearly documented in writing: most reputable surgeons offer one revision for under- or over-correction at cost, within 6 months.

What does the evidence say about ptosis surgery?

The clinical evidence base for ptosis surgery is mature, with two foundational papers — Putterman (MMCR, 1975) and Anderson & Beard (anterior levator advancement, 1979) — underpinning more than four decades of refinement.

• Anterior levator advancement — success rate (defined as MRD1 within 1 mm of intended at 6 months) is 85–95 per cent in published UK BOPSS audit data and large series (Berlin & Vest, Edmonson & Wulc, Carraway). Re-operation rate 8–12 per cent.
• Müller muscle conjunctival resection (MMCR) — success rate 90–95 per cent in well-selected phenylephrine-positive cases with levator function ≥ 10 mm. Predictability is excellent because the response to phenylephrine quantitatively predicts the post-op lift (Putterman nomogram and McCulley refinement).
• Frontalis sling — success rate 75–85 per cent in severe levator-poor ptosis (congenital, 3rd nerve palsy, CPEO, OPMD). Autologous fascia lata is the durability gold standard (10–20 year results), silicone slings are easier to revise but loosen earlier.
• Cochrane review on surgical interventions for involutional ptosis concludes that anterior and posterior approaches give equivalent functional outcomes in correctly-selected patients; selection by phenylephrine test and levator function is the dominant determinant of success.
• Combined ptosis + upper blepharoplasty — same-incision combined surgery does not worsen ptosis outcomes and addresses the visible dermatochalasis efficiently in a single operation.
• BOPSS national audit data — UK ptosis surgery infection rate < 0.5 per cent, haemorrhage requiring intervention < 1 per cent, lagophthalmos > 2 mm at 6 weeks 2–4 per cent, lid contour abnormality 3–6 per cent.
• Visual field benefit — ptosis correction restores 18–35 degrees of superior field on Humphrey 24-2 testing (Cahill et al., Battu et al.), comparable to or exceeding upper blepharoplasty alone.
• NICE guidance on functional eyelid surgery defines the threshold for medical commissioning (MRD1 ≤ 2 mm or documented visual field loss).

Anterior levator advancement vs MMCR vs frontalis sling: which is right for me?

The choice is dictated by the levator function and the phenylephrine response, not by patient preference or surgeon habit.

• Anterior levator advancement (Anderson 1979) — the workhorse operation for moderate aponeurotic ptosis with good levator function (≥ 8 mm). Skin-crease incision, levator aponeurosis dissected free of orbital septum, advanced and re-attached to the anterior tarsus with 6/0 Vicryl double-armed sutures, height adjusted with the patient sitting up on the table. Excellent contour control. Compatible with same-incision upper blepharoplasty.
• Müller muscle conjunctival resection (Putterman 1975) — posterior approach, no skin incision, no visible scar. Indicated when the phenylephrine 2.5 per cent test gives a 1.5–2 mm lift and the levator function is ≥ 10 mm. Putterman clamp grasps the conjunctiva and Müller's muscle 9–10 mm proximal to the tarsus, the tissue is excised, and the cut edges are closed with running 6/0 Vicryl. 20–30 minute operation. Excellent in mild ptosis with thyroid-related sympathetic over-action and in Horner's syndrome.
• Frontalis sling — for severe ptosis where the levator function is < 4 mm (congenital severe, 3rd nerve palsy, CPEO, OPMD, severe myogenic). The upper eyelid is mechanically suspended from the frontalis muscle via a sling of autologous fascia lata (Crawford technique) or pre-packed silicone (Crawford or Beard pentagonal pattern). The patient subsequently lifts the eyelid by raising the brow.
• Whitnall sling / superior tarsectomy / maximal levator resection — reserved for moderately severe ptosis (levator function 4–7 mm) where a sling is undesirable; technically demanding and best done by an oculoplastic specialist.
• Fasanella-Servat tarso-conjunctival resection — older posterior procedure largely superseded by MMCR; some surgeons retain it for mild ptosis where conjunctival sparing is unimportant.
• Adjustable suture techniques (Lucarelli) — permit fine-tuning of lid height in the first 1–5 post-op days; useful in revision surgery and challenging primary cases.
• Cross-procedure rule — if the phenylephrine test gives less than a 1 mm lift, the posterior approach is not predictable and an anterior levator advancement is preferred even if the levator function is good.

Who is a good candidate for ptosis surgery?

Candidacy is determined by the cause, the MRD1, the levator function, the phenylephrine response, the corneal protection (Bell's phenomenon, tear film, lagophthalmos), and the patient's general medical fitness for day-case oculoplastic surgery.

• Aponeurotic (involutional) ptosis with MRD1 ≤ 3 mm and levator function ≥ 10 mm — textbook candidate for either anterior levator advancement or MMCR depending on the phenylephrine response.
• Congenital ptosis with poor levator function (< 4 mm) — frontalis sling.
• Congenital ptosis with fair levator function (4–8 mm) — large levator resection (Berke or Mustardé modification) or Whitnall sling.
• Third nerve palsy (recovered or static, after 6–12 months observation) — frontalis sling, with caution about lagophthalmos given the impaired corneal sensation.
• Horner's syndrome (after underlying cause excluded) — MMCR is the operation of choice; the Müller muscle responds strongly to phenylephrine.
• Myasthenia gravis — medical control with pyridostigmine and/or immunomodulation first; surgery considered only if ptosis persists with stable disease.
• CPEO, OPMD, severe myogenic ptosis — bilateral frontalis sling with conservative lift (because of the absent Bell's phenomenon and reduced blink, the lid must be left slightly low to protect the cornea).
• Mechanical ptosis (chalazion, eyelid tumour, dermatochalasis) — treat the underlying lesion first; surgery for residual ptosis only if persists.
• Absolute contraindications — active eyelid infection, untreated thyroid eye disease with lid retraction, uncontrolled myasthenia, severe dry eye with corneal exposure, active herpes simplex keratitis.

NHS vs private ptosis surgery in the UK 2026

The NHS funds ptosis surgery when there is a documented functional impairment, not for cosmetic indications alone. The functional threshold differs slightly by commissioning region but typically requires MRD1 ≤ 2 mm and / or a documented superior visual field defect on Humphrey 24-2 or Goldmann perimetry with the eyelid in its resting position. NHS waits in 2026 are realistically 18–52 weeks from referral to surgery, depending on the trust's commissioning prioritisation and the oculoplastic subspecialty workload. NHS care is excellent — the practical limitations are timing, choice of consultant, and the fact that mild but symptomatic ptosis with an MRD1 of 2.5–3 mm often falls below the commissioning threshold and is left untreated.

Private ptosis surgery in the UK in 2026 typically offers a same-week consultant oculoplastic assessment, 2–4 week surgery booking, choice of surgeon, choice of technique within clinical indication, photographic documentation, and a structured 3-month outcome review with a documented revision policy. The medical standard of care is the same; the differences are wait time, choice and continuity of consultant, and the breadth of indication (private cases can include lower-threshold functional ptosis that the NHS would not commission).

Does private medical insurance cover ptosis surgery?

In 2026 most UK private medical insurers (Bupa, AXA Health, Aviva, Vitality, WPA) fund ptosis surgery when the case is documented as functional rather than cosmetic. Cosmetic-only ptosis surgery is not covered.

• Functional documentation required — MRD1 ≤ 2 mm and / or a documented superior visual field defect (typically > 12–25 per cent loss on Humphrey 24-2 or Goldmann III/4e) with the eyelid untaped, comparison with the taped lid showing field improvement, and a clinical letter explaining the impact on activities of daily living.
• CCSD / OPCS-4 codes — commonly used: C18.1 (correction of ptosis of eyelid by levator resection), C18.2 (correction of ptosis of eyelid by aponeurosis advancement), C18.3 (correction of ptosis of eyelid by tarsoconjunctival müllerectomy / MMCR), C18.4 (correction of ptosis of eyelid by frontalis suspension). The clinical letter should reference the relevant code.
• Pre-authorisation — always obtain in writing before surgery; verbal authorisation is not enough. Most insurers require the consultant letter, the perimetry printouts and the clinical photographs.
• Bilateral cases — both eyes are usually authorised in the same episode if both meet criteria; some insurers will only authorise the worse eye first.
• Cosmetic carve-out — if the ptosis is mild and predominantly aesthetic (MRD1 > 3 mm, no field defect) it falls outside cover; combined ptosis + cosmetic upper blepharoplasty can be partially covered (ptosis portion only).
• Excess and shortfall — check the policy excess and any shortfall against the consultant's fee schedule; some insurers cap surgeon fees below typical London consultant private rates.

Risks and side-effects of ptosis surgery

Ptosis surgery is well-tolerated and serious complications are rare, but every patient should understand the realistic risk profile before consenting.

• Under-correction — the most common imperfect outcome; the lid does not lift as much as intended. Rate 5–12 per cent depending on technique and case complexity; manageable with revision surgery or, in adjustable cases, with bedside suture adjustment in the first 1–5 days.
• Over-correction (lid retraction) — the lid sits too high. Rate 3–6 per cent; more common in MMCR if the phenylephrine response was over-interpreted. Manageable by lid massage in the first 2 weeks, then suture release or graded recession.
• Lagophthalmos — incomplete eyelid closure on attempted gentle eye closure, leading to dry eye, exposure keratitis. Common in the first 2–4 weeks (10–25 per cent), persistent at 6 weeks in 2–4 per cent. Managed with intensive lubrication, taping at night, lid massage; rarely needs surgical revision.
• Dry eye — pre-existing dry eye worsens transiently after ptosis surgery because of the increased palpebral fissure. Active screening and pre-treatment of dry eye is essential.
• Asymmetry — lid level mismatch > 0.5 mm at 3 months; rate 5–10 per cent. Often addressed by adjusting the contralateral lid (the "contralateral surgery" principle).
• Lid contour abnormality (peak, plateau, dip) — rate 3–6 per cent; predominantly avoidable with intra-operative table-sitting and contour check; revision is technically more demanding than lift adjustment.
• Lid crease abnormality — high crease, double crease, asymmetric crease; managed at the time of revision.
• Suture granuloma / cyst — rare with modern absorbable sutures; excision under local anaesthetic if symptomatic.
• Conjunctival irritation (MMCR specifically) — from the buried conjunctival suture; resolves over 4–6 weeks; rare suture-extrusion needs trimming.
• Frontalis sling extrusion / infection — silicone slings 8–15 per cent at 5 years; fascia lata < 3 per cent. Late infection mandates sling removal.
• Haemorrhage — bruising is normal; serious bleeding requiring intervention < 1 per cent; retrobulbar haemorrhage with sight-threatening pressure is extremely rare and is a surgical emergency.
• Infection — < 0.5 per cent in BOPSS UK audit data.
• Visible scar — anterior approach uses the natural skin-crease line and is generally imperceptible by 3–6 months; MMCR posterior approach leaves no skin scar.
• Need for revision — 8–12 per cent across techniques. A reputable surgeon's written quote should include a revision policy.

What to expect after ptosis surgery

Most patients are home within 2–3 hours of surgery and back to non-strenuous work within 1–2 weeks, with a 3-month timeline to the final cosmetic result.

• Day 0–1 — mild discomfort, bruising and swelling around the upper lid; ice packs for 10 minutes hourly while awake. Vision is normal; the operated lid may sit slightly high (deliberate over-correction in some techniques to allow for early settle).
• Day 2–7 — bruising peaks at 48–72 hours and settles thereafter. Topical antibiotic ointment to the suture line three times daily. Lubricating drops 4–6 times daily and lubricating ointment at night to protect the cornea.
• Day 7–10 — skin sutures removed (anterior approach); MMCR sutures are absorbable and need no removal. Photographs taken.
• Week 2–6 — bruising resolves, lid sits closer to its intended position, lagophthalmos (if any) reduces. Return to non-strenuous work after 1–2 weeks, light exercise after 2 weeks.
• Week 6 — clinical contour review with photographic comparison; minor adjustments (if needed) planned at this point. Resume contact lens wear, eye make-up, swimming.
• Month 3 — final outcome with objective MRD1 measurement, symmetry within 0.5 mm and patient-reported outcome.
• Driving — most patients can drive at day 7–14 once the visual field is restored, the swelling settled and they meet the DVLA visual standard (Snellen 6/12 with both eyes, 120-degree horizontal field).
• Long-term — recurrence at 10 years 8–15 per cent for anterior approach (less for MMCR), more for frontalis sling; revision is a relatively straightforward redo procedure.

How to choose a UK ptosis surgery clinic in 2026

The single biggest determinant of a good ptosis outcome is the surgeon's sub-specialty training and case volume. Choose carefully.

• GMC specialist registered consultant ophthalmologist with documented oculoplastic fellowship training (e.g. BOPSS-recognised or ASOPRS / ESOPRS equivalent).
• Annual ptosis volume — ask: at least 50–100 ptosis procedures per year for a primary case, ≥ 20 per year for revision work.
• CQC-registered theatre with a CQC rating of Good or Outstanding; ask for the inspection report.
• Photographic documentation protocol — pre-op, immediate post-op, 6-week, 3-month; standardised lighting, head position, eyelid taped and untaped.
• Phenylephrine-driven case selection — surgeons who routinely do MMCR are typically the most rigorous at case selection; over-reliance on anterior surgery regardless of phenylephrine is a flag.
• Audit data — the surgeon should be willing to share their personal under-correction, over-correction, asymmetry and revision rates.
• Written, itemised quote with explicit revision policy.
• Insurance fluency — experienced practice manager who handles Bupa, AXA, Aviva, Vitality, WPA pre-authorisation routinely.
• Aftercare access — 24-hour out-of-hours contact for the first 2 weeks.

Frequently asked questions

How much does private ptosis surgery cost in the UK in 2026?

UK 2026 self-pay ptosis surgery costs £2,800–£6,500 per eye, depending on technique: anterior levator advancement (Anderson 1979) is typically £3,500–£5,500 per eye, Müller muscle conjunctival resection (Putterman 1975) is £2,800–£4,500 per eye, and a frontalis sling for severe levator-poor disease is £4,500–£6,500 per eye. Bilateral levator advancement is typically £5,500–£8,500 (reflecting a ~25 per cent bilateral discount). The fee covers consultant oculoplastic assessment, phenylephrine 2.5 per cent testing, MRD1 and levator function measurement, visual field perimetry, day-case theatre under local anaesthetic with optional sedation, and structured 1-week, 6-week and 3-month follow-up.

What is the difference between anterior levator advancement and MMCR?

The anterior approach (Anderson 1979 levator advancement) is performed through a skin-crease incision and works by re-attaching the dehisced levator aponeurosis to the anterior tarsus — it is the workhorse operation for moderate aponeurotic ptosis with good levator function. The posterior approach (Putterman 1975 MMCR) is performed through the conjunctiva on the back of the eyelid, leaves no visible skin scar, and works by shortening Müller's muscle — it is the operation of choice when the phenylephrine 2.5 per cent test gives a 1.5–2 mm lift and the levator function is ≥ 10 mm. The choice is dictated by the phenylephrine test, not surgeon preference. See our MMCR guide for the posterior approach in detail.

How long does ptosis surgery take and is it painful?

Ptosis surgery takes 30–60 minutes per eye as a day-case under local anaesthetic with optional sedation. You are awake but the eyelid is fully numb. There is no pain during surgery, just a sense of pressure and gentle pulling. Most surgeons prefer the patient to be awake for the anterior approach so the lid height can be checked on the table with the patient sitting up. Postoperatively there is mild discomfort, bruising and swelling for 2–7 days, typically controlled with paracetamol.

What is the phenylephrine test and why does it matter?

The phenylephrine 2.5 per cent test is a topical eye drop that stimulates Müller's muscle, mimicking the lift that a posterior MMCR would deliver. After 5 minutes the eyelid is re-measured: a 1.5–2 mm rise predicts a successful MMCR; less than 1 mm of lift means the posterior approach is unpredictable and an anterior levator advancement is preferred. It is the single most important pre-operative decision point in ptosis surgery selection, and any quote that omits it is incomplete.

Will the NHS pay for my ptosis surgery?

Yes, when the case is documented as functional. NHS commissioning typically requires an MRD1 ≤ 2 mm and / or a documented superior visual field defect on Humphrey 24-2 or Goldmann perimetry with the eyelid untaped. Realistic NHS waits in 2026 are 18–52 weeks from referral to surgery depending on the trust. Mild ptosis with an MRD1 of 2.5–3 mm is usually below the NHS commissioning threshold and is the most common reason patients self-pay or use private medical insurance.

Will my private medical insurance cover ptosis surgery?

In 2026 Bupa, AXA Health, Aviva, Vitality and WPA generally cover ptosis surgery when documented as functional (MRD1 ≤ 2 mm and / or a documented superior visual field defect > 12–25 per cent on Humphrey 24-2 or Goldmann III/4e with the eyelid untaped). The clinical letter must reference the relevant OPCS-4 code (C18.1, C18.2, C18.3, C18.4) and include taped vs untaped perimetry. Cosmetic-only ptosis is not covered. Always pre-authorise in writing.

How long does the lid take to settle?

Bruising and swelling settle over 2–3 weeks, the lid contour is essentially final by 6 weeks, and the absolute final outcome is at 3 months once the levator complex has fully scarred into its new position. Sutures (anterior approach) come out at day 7–10; MMCR uses absorbable sutures that need no removal. Most patients return to non-strenuous work after 1–2 weeks.

Can I combine ptosis surgery with upper blepharoplasty?

Yes, very commonly. The same skin-crease incision is used, the orbital fat and excess skin are addressed at the start of the procedure, the levator advancement is then performed beneath, and the skin is closed in one. Combined surgery does not worsen ptosis outcomes and is the most efficient way to address both the eyelid position and the surrounding dermatochalasis. Typical UK 2026 combined price £4,800–£7,000 per eye. See the companion private blepharoplasty cost guide.

What about non-surgical ptosis treatments like Upneeq or a glasses crutch?

Upneeq (oxymetazoline 0.1 per cent eye drops) is licensed for acquired aponeurotic ptosis and gives a temporary 1–2 mm lift via Müller muscle stimulation, lasting around 6–8 hours per dose. It is useful as a diagnostic aid (similar mechanism to phenylephrine), as a bridge before surgery, and as a permanent option in patients who decline surgery or for whom surgery is contraindicated. Daily long-term cost is substantial. A "ptosis crutch" fitted to spectacles is a low-tech alternative for severe ptosis where surgery is contraindicated (e.g. severe myasthenia gravis with active fatigability, CPEO with absent Bell's phenomenon). Neither is a substitute for surgery in a fit patient with a functional ptosis.

Will the scar be visible?

For the anterior approach, the incision is placed in the natural upper-eyelid crease (typically 7–9 mm above the lash line in Caucasians, 5–7 mm in East Asians); it is essentially imperceptible by 3–6 months when the lids are open and barely visible even on close inspection with the eyes closed. For the posterior approach (MMCR) there is no skin incision at all and therefore no visible scar.

When can I drive after ptosis surgery?

Most patients can drive at 7–14 days once the swelling has settled, the operated eye sits at the intended height and they meet the DVLA visual standard: Snellen 6/12 with both eyes open and a 120-degree horizontal field of vision. Driving should not resume while the bruising or eyelid swelling restricts the upper field, or while sedation effects remain.

Can ptosis come back after surgery?

Recurrence is possible. For the anterior approach it is approximately 8–15 per cent at 10 years, often from progressive age-related dehiscence of the underlying levator aponeurosis — the same mechanism that caused the original problem. MMCR has a slightly lower recurrence rate. Frontalis sling has higher recurrence (silicone slings 8–15 per cent at 5 years; autologous fascia lata < 3 per cent). Recurrence is treated by a relatively straightforward revision procedure.

Anterior levator advancement vs MMCR vs frontalis sling - which is right for me?

Anterior levator advancement is the workhorse operation for moderate aponeurotic ptosis with good levator function. MMCR is the posterior operation of choice when the phenylephrine 2.5 per cent test gives a 1.5–2 mm lift and the levator function is ≥ 10 mm. Frontalis sling is reserved for severe ptosis with poor levator function (< 4 mm) — congenital severe, 3rd nerve palsy, CPEO, OPMD — where the eyelid must be mechanically suspended from the frontalis muscle. The decision is always made by a consultant oculoplastic surgeon after MRD1, levator function and phenylephrine testing; see the ptosis surgery options overview for the comparison in detail.

Methodology and sources

This UK 2026 patient pricing and pathway guide was prepared by the Eye Surgery Clinic editorial team and reviewed by a UK GMC-registered consultant ophthalmologist with oculoplastic subspecialty interest. Pricing reflects a CQC-registered UK oculoplastic sample audited against published 2024 to 2026 self-pay tariffs from the major UK oculoplastic centres. Clinical statements are anchored on:

• Putterman AM, Urist MJ. Müller muscle-conjunctival resection. Arch Ophthalmol 1975; 93: 619-623
• Anderson RL, Beard C. The levator aponeurosis. Attachments and their clinical significance. Arch Ophthalmol 1977; 95: 1437-1441
• Beard C. Ptosis (textbook), 3rd edn, Mosby 1981; classification and surgical decision framework
• Edmonson BC, Wulc AE. Ptosis evaluation and management. Otolaryngol Clin North Am 2005
• Carraway JH. Ptosis surgery; aponeurotic repair and contemporary technique refinements
• McCulley TJ et al. Predicting the success of Müllerectomy by the phenylephrine response
• British Oculoplastic Surgery Society (BOPSS) national ptosis audit
• Royal College of Ophthalmologists oculoplastic subspecialty commissioning guidance
• AAO Oculoplastics and Reconstructive Surgery Preferred Practice Pattern (Pediatric and Adult Ptosis)
• Cochrane Database of Systematic Reviews on surgical interventions for involutional ptosis
• Care Quality Commission (CQC) inspection reports for major UK oculoplastic units
• General Medical Council (GMC) Good Medical Practice and consent guidance

This page is editorial and educational. It is not personalised medical advice. Ptosis suitability and the specific surgical technique can only be confirmed by an in-person consultation with a UK GMC-registered consultant ophthalmologist with oculoplastic subspecialty interest, including MRD1, levator function (Berke), phenylephrine response, corneal protection assessment and visual field perimetry.

Book your UK ptosis surgery consultation

Speak directly to a UK GMC-registered consultant ophthalmologist with oculoplastic subspecialty interest. Same-week consultation slots are usually available. Slit-lamp, MRD1, MRD2, levator function (Berke), phenylephrine 2.5 per cent test, Bell's phenomenon, tear film, lagophthalmos, photographic documentation and visual field perimetry for insurance documentation are included. Confidential, no-obligation review of whether anterior levator advancement, MMCR or frontalis sling is right for you.

Related reading: Private blepharoplasty cost UK · Private MMCR (Müller muscle conjunctival resection) London · Private frontalis sling ptosis surgery London · Ptosis surgery options overview